1
|
Galvin JE, Cummings JL, Benea ML, de Moor C, Allegri RF, Atri A, Chertkow H, Paquet C, Porter VR, Ritchie CW, Sikkes SAM, Smith MR, Grassi CM, Rubino I. Generating real-world evidence in Alzheimer's disease: Considerations for establishing a core dataset. Alzheimers Dement 2024. [PMID: 38706421 DOI: 10.1002/alz.13785] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2023] [Revised: 01/18/2024] [Accepted: 02/12/2024] [Indexed: 05/07/2024]
Abstract
Ongoing assessment of patients with Alzheimer's disease (AD) in postapproval studies is important for mapping disease progression and evaluating real-world treatment effectiveness and safety. However, interpreting outcomes in the real world is challenging owing to variation in data collected across centers and specialties and greater heterogeneity of patients compared with trial participants. Here, we share considerations for observational postapproval studies designed to collect harmonized longitudinal data from individuals with mild cognitive impairment or mild dementia stage of disease who receive therapies targeting the underlying pathological processes of AD in routine practice. This paper considers key study design parameters, including proposed aims and objectives, study populations, approaches to data collection, and measures of cognition, functional abilities, neuropsychiatric status, quality of life, health economics, safety, and drug utilization. Postapproval studies that capture these considerations will be important to provide standardized data on AD treatment effectiveness and safety in real-world settings.
Collapse
Affiliation(s)
- James E Galvin
- Comprehensive Center for Brain Health, Department of Neurology, University of Miami Miller School of Medicine, Boca Raton, Florida, USA
| | - Jeffrey L Cummings
- Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, University of Nevada Las Vegas (UNLV), Las Vegas, Nevada, USA
| | | | | | - Ricardo F Allegri
- Instituto de Investigaciones Neurológicas Fleni, Buenos Aires, Argentina
- Departamento de Neurociencias, Universidad De La Costa (CUC), Barranquilla, Atlántico, Colombia
| | - Alireza Atri
- Banner Sun Health Research Institute, Sun City, Arizona, USA
- Center for Brain/Mind Medicine, Department of Neurology, Brigham and Women's Hospital - Main Campus, Boston, Massachusetts, USA
- Harvard Medical School, Boston, Massachusetts, USA
| | - Howard Chertkow
- Rotman Research Institute, Baycrest Health Sciences, Toronto, Ontario, Canada
| | - Claire Paquet
- Université de Paris GHU AP-HP Nord Lariboisière Hospital, Paris, France
| | - Verna R Porter
- Pacific Brain Health Center, Pacific Neuroscience Institute, Santa Monica, California, USA
- Saint John's Cancer Institute, Santa Monica, California, USA
| | | | - Sietske A M Sikkes
- Alzheimer Center Amsterdam, Amsterdam University Medical Center, Amsterdam, The Netherlands
- Department of Clinical, Neuro- and Developmental Psychology, Vrije Universiteit (VU) Amsterdam, Amsterdam, The Netherlands
| | | | | | | |
Collapse
|